scholarly article | Q13442814 |
P356 | DOI | 10.1191/0961203304LU1080OA |
P8608 | Fatcat ID | release_xj2n5tsnb5dezleztpujtpixky |
P698 | PubMed publication ID | 15540510 |
P50 | author | Josep Font | Q73474655 |
Miguel Ingelmo | Q73600642 | ||
Manuel Ramos-casals | Q42646201 | ||
Sonia Segura | Q42882490 | ||
Ricard Cervera i Segura | Q53547424 | ||
Antonio-J Chamorro | Q56956958 | ||
P2093 | author name string | J Yagüe | |
M T Campoamor | |||
G Salvador | |||
J C Botero | |||
P2860 | cites work | Complement. First of two parts | Q28210663 |
Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus | Q29614922 | ||
Morbidity and mortality in systemic lupus erythematosus during a 5-year period. A multicenter prospective study of 1,000 patients. European Working Party on Systemic Lupus Erythematosus | Q33329033 | ||
Complement C3 activation is required for antiphospholipid antibody-induced fetal loss | Q33340713 | ||
Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients | Q33341941 | ||
Predictive value of complement profiles and anti-dsDNA in systemic lupus erythematosus | Q33556592 | ||
International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop | Q33685960 | ||
Clinical predictors of fetal and maternal outcome in systemic lupus erythematosus: a prospective study of 103 pregnancies | Q34131724 | ||
Update on complement in the pathogenesis of systemic lupus erythematosus | Q34793539 | ||
Cardiac valvulopathy in the antiphospholipid syndrome | Q34981341 | ||
Outcome of a cohort of 300 patients with systemic lupus erythematosus attending a dedicated clinic for over two decades | Q35551526 | ||
Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus. A long-term, prospective study | Q41192552 | ||
A decrease in complement is associated with increased renal and hematologic activity in patients with systemic lupus erythematosus | Q43772908 | ||
Immunologic factors and clinical activity in systemic lupus erythematosus | Q47817323 | ||
Cryoglobulinemia in systemic lupus erythematosus: Prevalence and clinical characteristics in a series of 122 patients | Q56907681 | ||
Cryoglobulinemia | Q56907690 | ||
Laboratory tests as predictors of disease exacerbations in systemic lupus erythematosus. Why some tests fail | Q58161488 | ||
P433 | issue | 10 | |
P921 | main subject | systemic lupus erythematosus | Q1485 |
antiphospholipid syndrome | Q582207 | ||
primary antiphospholipid syndrome | Q63878006 | ||
P304 | page(s) | 777-783 | |
P577 | publication date | 2004-01-01 | |
P1433 | published in | Lupus | Q6704846 |
P1476 | title | Hypocomplementemia in systemic lupus erythematosus and primary antiphospholipid syndrome: prevalence and clinical significance in 667 patients | |
P478 | volume | 13 |
Q37318783 | Antiphospholipid antibodies and atherosclerosis: insights from systemic lupus erythematosus and primary antiphospholipid syndrome |
Q48159962 | Antiphospholipid antibodies and non-thrombotic manifestations of systemic lupus erythematosus |
Q52852275 | Atherosclerosis in primary antiphospholipid syndrome. |
Q99583920 | Autoimmunity as the comet tail of COVID-19 pandemic |
Q40355684 | BF*F allotype of the alternative pathway of complement: A marker of protection against the development of antiphospholipid antibodies in patients with systemic lupus erythematosus |
Q33398064 | BioPlex 2200 multiplexed system: simultaneous detection of anti-dsDNA and anti-chromatin antibodies in patients with systemic lupus erythematosus |
Q38657043 | Clinical Risk Assessment in the Antiphospholipid Syndrome: Current Landscape and Emerging Biomarkers |
Q34790651 | Clinical, radiographic characteristics and immunomodulating changes in neuromyelitis optica with extensive brain lesions |
Q37638376 | Complement activation and pregnancy failure |
Q38109340 | Complement inhibition in cancer therapy |
Q33667257 | Complete complement deficiency in a large cohort of familial systemic lupus erythematosus |
Q38139836 | Differential diagnosis of glomerular disease: a systematic and inclusive approach |
Q39900855 | Digital vasculitis in systemic lupus erythematosus: a minor manifestation of disease activity? |
Q39586997 | Endothelial progenitor dysfunction associates with a type I interferon signature in primary antiphospholipid syndrome |
Q28301662 | Hypercomplementemia at relapse in patients with anti-aquaporin-4 antibody |
Q61453809 | Hypocomplementemia as a Risk Factor for Organ Damage Accrual in Patients with Systemic Lupus Erythematosus |
Q33428578 | Lupus anticoagulant, disease activity and low complement in the first trimester are predictive of pregnancy loss |
Q44220435 | Lupus erythematosus. Wide range of symptoms through clinical variation, associated diseases and imitators |
Q28196178 | Management of the antiphospholipid syndrome |
Q64248332 | Opposite Profiles of Complement in Antiphospholipid Syndrome (APS) and Systemic Lupus Erythematosus (SLE) Among Patients With Antiphospholipid Antibodies (aPL) |
Q36479278 | Progress and Trends in Complement Therapeutics |
Q84355517 | Study on clinical features and complications with systemic lupus erythematosus (SLE) activity in Chinese Han population |
Q36813467 | T cells and in situ cryoglobulin deposition in the pathogenesis of lupus nephritis |
Q44645053 | Trisomy 21 causes changes in the circulating proteome indicative of chronic autoinflammation. |
Search more.